1311PDHealth-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial. (23rd October 2018) - Rinke, A; Neary, M P; Eriksson, J; Hunger, M; Doan, T; Karli, D; Arnold, R